USA - New York Stock Exchange - NYSE:MYOV - BMG637AM1024 - Common Stock
ChartMill assigns a Buy % Consensus number of 76% to MYOV. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-26 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-10-25 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-10-24 | Baird | Downgrade | Outperform -> Neutral |
| 2022-08-09 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2022-07-28 | Goldman Sachs | Maintains | Neutral |
| 2022-05-11 | Goldman Sachs | Maintains | Neutral |
| 2022-04-13 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-05 | SVB Leerink | Maintains | Market Perform |
| 2021-10-27 | SVB Leerink | Maintains | Market Perform |
| 2021-09-09 | SVB Leerink | Initiate | Market Perform |
| 2021-02-12 | SVB Leerink | Maintains | Market Perform |
10 analysts have analysed MYOV and the average price target is 27.54 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 26.98.
The consensus rating for Myovant Sciences Ltd (MYOV) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering Myovant Sciences Ltd (MYOV) is 10.